XML 36 R6.htm IDEA: XBRL DOCUMENT

Organization and Business	6 Months Ended
Organization and Business	Jun. 30, 2013
Business Disclosure Abstract
Organization and Business	Supernus Pharmaceuticals, Inc. Notes to Consolidated Financial Statements For the Three and Six Months Ended June 30, 2013 and 2012 (unaudited) 1. Organization and Business Supernus Pharmaceuticals, Inc. (the Company) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company has two proprietary products and several proprietary product candidates in clinical development that address the epilepsy and attention deficit hyperactivity disorder markets. The Company is currently focused on the commercialization of Oxtellar XR and the anticipated commercialization of Trokendi XR. Oxtellar XR received final approval from the Food and Drug Administration (FDA) on October 19, 2012 and the Company began the commercial launch of this product on February 4, 2013. The Company anticipates the commercial launch of Trokendi XR during the third quarter of 2013 pending receipt of final approval from the FDA.